Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00994890 · ClinicalTrials.gov registry record · Phase 2
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 679
- Enrollment target
NCT00994890: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT00994890 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 679 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (411% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00994890, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 679 participants
- Enrollment target
Study Summary
This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg, and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times during the study treatment period.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days a
Interventions
- DRUG Tanezumab 2.5 mg
- DRUG Tanezumab 5 mg
- DRUG Tanezumab 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2009-11-17 |
| Est. Completion | 2011-03-01 |
| Phase | Phase 2 |
Why NCT00994890 stopped before completion
NCT00994890 is an interventional study that assigns participants to a tested intervention. The registered 679 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (411% higher).
The record links to 0 conditions, and to 3 interventions - of which Tanezumab 2.5 mg is the first listed.
NCT00994890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00994890 about?
NCT00994890 is a clinical study titled "A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections". This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg, and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times during the study treatment period.
What is the current status of trial NCT00994890?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 679 participants. The study started on 2009-11-17. Estimated completion is 2011-03-01.
What interventions are being tested in trial NCT00994890?
The interventions under investigation include: Tanezumab 2.5 mg (DRUG), Tanezumab 5 mg (DRUG), Tanezumab 10 mg (DRUG).
Who is sponsoring clinical trial NCT00994890?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00994890's enrollment target sits among peer trials
679 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI